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Background: Complement factor H-related 
protein 4 (CFHR4) has been shown to interact 
with C3b. 
Results: Binding of C3b to CFHR4 allows the 
formation of an active alternative pathway C3 
convertase. 
Conclusion: CFHR4 activates complement via the 
alternative pathway. 
Significance: A novel function is identified for 
CFHR4 that stands in contrast with the 
complement inhibitory activity of factor H. 
 
SUMMARY 
Human complement factor H-related protein 
(CFHR) 4 belongs to the factor H family of 
plasma glycoproteins that are composed of 
short consensus repeat (SCR) domains. While 
factor H is a well-known inhibitor of the 
alternative complement pathway, the functions 
of the CFHR proteins are poorly understood. 
CFHR4 lacks SCRs homologous to the 
complement inhibitory domains of factor H 
and, accordingly, has no significant 
complement regulatory activities. We have 
previously shown that CFHR4 binds C-reactive 
protein via its most N-terminal SCR, which 
leads to classical complement pathway 
activation. CFHR4 binds C3b via its C-
terminus, but the significance of this interaction 
is unclear. Therefore, we set out to clarify the 
functional relevance of C3b binding by CFHR4. 
Here, we report a novel role for CFHR4 in the 
complement system. CFHR4 serves as a 
platform for the assembly of an alternative 
pathway C3 convertase by binding C3b. This is 
based on the sustained ability of CFHR4-bound 
C3b to bind factor B and properdin, leading to 
an active convertase that generates C3a and 
C3b from C3. The CFHR4-C3bBb convertase is 
less sensitive to the factor H-mediated decay 
compared to the C3bBb convertase. CFHR4 
mutants containing exchanges of conserved 
residues within the C-terminal C3b binding site 
showed significantly reduced C3b binding and 
alternative pathway complement activation. In 
conclusion, our results suggest that, in contrast 
to the complement inhibitor factor H, CFHR4 
acts as an enhancer of opsonization by 
promoting complement activation. 
Complement is a powerful effector system of 
innate immunity, with major roles in the 
elimination of microbes, inflammatory processes, 
disposal of cellular debris, and modulation of 
adaptive immunity (1). A multi-level regulation 
ensures complement activation on dangerous 
surfaces but prevents its harmful effects on host 
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cells and tissues. This is achieved by the 
expression of complement inhibitors on host cell 
surfaces and the absence of those on foreign or 
altered self surfaces, as well as by soluble 
regulators having distinct binding specificities for 
different surfaces (2). 
The plasma glycoprotein factor H (FH) 1 is 
the major soluble inhibitor of the alternative 
complement pathway (AP) (3, 4). It prevents the 
formation of the AP C3 convertase C3bBb by 
blocking the binding of factor B (FB) to C3b, and 
accelerates the decay of existing C3 convertases 
by displacing Bb. It also acts as a cofactor for the 
serine protease factor I (FI) in the cleavage of C3b 
to inactive C3b (iC3b), which can no longer form 
a convertase (4, 5). By these mechanisms, FH 
inhibits the amplification of the complement 
cascade both in fluid phase and on the surface of 
host cells (3, 4). 
FH, its splicing variant complement factor 
H-like protein 1 (CFHL1), and five complement 
factor H-related proteins (CFHR1-CFHR5), which 
are encoded by separate genes, constitute the 
human factor H protein family (6). FH is 
composed of 20 short consensus repeat (SCR) 
domains, CFHL1 contains SCRs 1-7 of FH, and 
the CFHR proteins consist of four to nine SCRs 
that are homologous to various domains of FH. 
Whereas CFHL1 shares the complement inhibitory 
activities of FH, the physiological roles of the 
CFHR proteins are less well understood. 
CFHR4 is detected in human plasma as 
two different glycoproteins. The 86-kDa long 
isoform termed CFHR4A consists of nine SCRs 
(7). The ~45-kDa shorter isoform termed CFHR4B 
is composed of five SCRs that represent SCR1 and 
SCRs 6-9 of CFHR4A (Figure 1) (7, 8). In 
CFHR4A, SCRs 1-4 and SCRs 5-8 are highly 
related based on nucleotide and amino acid 
sequence identity, likely as a result of an 
intramolecular duplication (Figure 1) (7). 
Like all CFHRs, both CFHR4 isoforms 
lack SCRs homologous to the N-terminal 
complement inhibitory domains SCRs 1-4 of FH 
and CFHL1. In agreement with this, no significant 
cofactor- and convertase decay accelerating 
activities have been reported for CFHR4B (9). The 
two most C-terminal domains of CFHR4A and 
CFHR4B are homologous to the C-terminal FH 
domains SCRs 19-20 that contain C3b/C3d 
binding sites. CFHR4B has been shown to bind 
the C3d region of C3b via its C-terminal SCRs 4-5 
(9, 10). However, except for a slight enhancement 
of the cofactor activity of FH in the presence of 
high (and rather non-physiological) CFHR4B 
concentrations (9), no significant functions have 
been associated with this C3b binding capacity. 
The CFHR4A isoform has not yet been 
characterized for its interaction with C3b and 
complement regulatory activity. 
Recently, we described native pentameric 
C-reactive protein (CRP) as a ligand for CFHR4A 
and CFHR4B, and showed that this interaction via 
a binding site in SCR1 leads to enhanced 
opsonization of necrotic cells with CRP and 
promotes complement activation via C4-dependent 
pathways (11, 12).  
This study was designed to investigate the 
significance of C3b binding by CFHR4. We 
describe a novel function for CFHR4 in 
complement activation by providing a platform for 
the assembly of an active AP C3 convertase. 
Thereby, and in marked contrast to FH, CFHR4 
enhances complement activation via its interaction 
with C3b. 
 
EXPERIMENTAL PROCEDURES 
 
Proteins, sera and antibodies 
Cloning and recombinant expression of CFHR4A 
as well as the CFHR4A deletion mutants SCR1-3, 
SCR2-4, SCR4-9, SCR5-7 and SCR8-9 were 
described (11, 12). CFHR4B, the CFHR4B 
mutants D221G and D221G/K290A, as well as 
CFHL1 were generated via gene synthesis 
(GenScript, Piscataway, NJ, USA) and subcloned 
into the baculovirus expression vector pBSV-8His 
(13). The proteins were expressed in Spodoptera 
frugiperda (Sf9) cells and purified by nickel 
affinity chromatography. 
Complement components C3b, C3d, FH 
and FI as well as recombinant human CRP were 
purchased from Merck Biosciences (Schwalbach, 
Germany). C3 was from Complement Technology 
(Tyler, TX, USA). Factor D and properdin were 
from Quidel (TECOmedical, Bünde, Germany), 
human serum albumin (HSA) was from Sigma-
Aldrich (Taufkirchen, Germany) and bovine serum 
albumin (BSA) was purchased from Applichem 
(Darmstadt, Germany). Normal human serum 
(NHS) was purchased from Sigma-Aldrich and 
PAA Laboratories (Cölbe, Germany) or was 
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collected from healthy individuals after informed 
consent. FB-depleted serum was from Quidel and 
C2-depleted serum was purchased from Merck 
Biosciences. 
A novel CFHR4 antiserum was raised by 
immunizing rabbits with the recombinant 
CFHR4A fragment SCR2-4. The histidine tag of 
SCR2-4 was cleaved off with recombinant bovine 
enterokinase light chain according to the 
manufacturer’s protocol (New England Biolabs, 
Frankfurt am Main, Germany). Enterokinase was 
removed with trypsin inhibitor agarose (Sigma-
Aldrich). Treatment of rabbits was conducted by 
BioGenes (Berlin, Germany) in accordance with 
German animal welfare regulations. 
Monoclonal anti-CFHR4 antibody 
(MAB5980) was purchased from R&D Systems 
(Wiesbaden, Germany). Horseradish peroxidase 
(HRP)-conjugated goat anti-human C3, which 
does not recognize C3d, was obtained from MP 
Biomedicals (Solon, OH, USA). Rabbit anti-
human C3d was from Dako (Hamburg, Germany), 
goat anti-human FH from Complement 
Technology, goat anti-human CRP and anti-human 
FB from Merck. Monoclonal anti-properdin was 
purchased from Quidel. HRP-conjugated swine 
anti-rabbit, rabbit anti-goat and rabbit anti-mouse 
antibodies were from Dako. 
 
Microtiter plate binding assays (ELISA) 
Assays were conducted in Tris-buffered saline 
(TBS), pH 7.4, containing 140 mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2 and 10 mM Tris ultra, using 
MaxiSorp microtiter plates (Nunc, Wiesbaden, 
Germany). Proteins were immobilized overnight at 
4°C. For the washing steps, TBS containing 0.02% 
Tween-20 (Sigma-Aldrich) was used. Remaining 
binding sites were blocked with 3% dry milk in 
TBS containing 0.02% Tween-20 for 2 h at 20°C. 
If not stated otherwise, ligands/serum samples 
were added for 30 min at 37°C. Antibodies were 
added for 45 min at 20°C. TMB PLUS Substrate 
(Kem-En-Tec Diagnostics, Taastrup, Denmark) 
was used for the visualization and the absorbance 
was measured at 450 nm. 
 
Determination of CFHR4 plasma concentration 
CFHR4 plasma concentration was determined in 
sandwich ELISA using immobilized monoclonal 
mouse anti-CFHR4 as catch antibody and the 
CFHR4 rabbit antiserum as detection antibody. 
Both the monoclonal antibody and the antiserum 
recognize the two CFHR4 isoforms (data not 
shown). Serum samples were diluted in TBS 
without CaCl2 and MgCl2 containing 10 mM 
EDTA to prevent complement activation. 
Calculation of CFHR4 content in serum samples 
was based on duplicate serial dilutions from two 
independent experiments. Results were obtained 
by four parameter logistic analysis of recombinant 
CFHR4A standard curves in SigmaPlot 10 (Systat 
Software, Erkrath, Germany). 
 
Assays with serum-opsonized yeast cells 
Saccharomyces cerevisiae strain ATCC9763 
(American Type Culture Collection, Manassas, 
VA, USA) was cultured in YPD medium shaking 
over night at 30°C. Cells were harvested, washed 
three times with TBS and immobilized in 
microtiter plates for 30 min at 20°C. Saturation of 
the well surface with bound yeast cells was 
controlled by microscopic analysis throughout the 
experiment. Unbound cells were washed away 
and, after blocking, wells were incubated with 
TBS containing 5% NHS or with TBS only for 
30 min at 37°C. After incubation with FH or 
CFHR4A (100 nM each), the binding of these 
proteins as well as the deposition of C3 fragments 
were analyzed by ELISA. 
 
Cofactor assays 
Cofactor activity of CFHR4A and enhancement of 
FH cofactor activity were determined in fluid-
phase C3b cleavage assays. C3b (530 ng) and FI 
(90 ng) were incubated alone or in combination 
with FH (150 ng), CFHL1 (55 ng) and CFHR4A 
(1.3 µg) for 45 min at 37°C in a final volume of 
15 µl in TBS. Reactions were stopped by the 
addition of reducing SDS-sample buffer. Samples 
were separated on 11% SDS-PAGE and subjected 
to Western blot analysis using HRP-conjugated 
anti-C3 antibody. A chemiluminescent detection 
kit (Applichem) was used to visualize the protein 
bands. 
 
Convertase assays 
C3bBb convertases were generated on C3b, 
immobilized at 5 µg/ml in microtiter plate wells, 
by the addition of FB (2 µg/ml), factor D 
(0.1 µg/ml), properdin (4 µg/ml) and BSA (10 
µg/ml) in 50 µl for 30 min at 37°C. Decay 
acceleration was analyzed by the addition of 
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increasing concentrations of CFHR4A, FH and 
HSA for 30 min at 37°C. Remaining intact 
convertases were detected with anti-FB antiserum. 
Convertases were assembled on 
immobilized CFHR4A or its deletion fragments 
SCR1-3 and SCR4-9 (100 nM) in the same way as 
described for the C3bBb convertase after 
preincubation with 5 µg/ml C3b for 30 min at 
37°C. In some experiments, CFHR4A was 
incubated with 10 µg/ml CRP prior to the addition 
of C3b and building up the convertase. Activity of 
the convertases was measured by adding 10 µg/ml 
C3 for 1 h at 37°C and analyzing the supernatant 
for generated C3a fragments using a C3a ELISA 
kit (Quidel). 
 
Complement activation assays 
CFHR4A, CFHR4B, SCR1-3, SCR4-9, FH and 
HSA were immobilized in equimolar amounts 
(100 nM) and incubated with 5% NHS for 30 min 
at 37°C. To measure AP activation, TBS 
containing 3 mM MgCl2 and 5 mM EGTA was 
used. Deposition of C3b, FB and properdin was 
measured by ELISA using the respective 
antibodies. 
 
Sequence analysis 
Protein sequences were aligned and analyzed with 
the MegAlign module of the Lasergene 7 software 
(DNASTAR, Madison, WI, USA) using the Jotun-
Hein method. 
 
RESULTS 
 
CFHR4 serum concentration 
In order to establish the physiological 
concentration of CFHR4, we determined CFHR4 
concentrations in eleven serum samples from 
single donors and in four different pooled sera. 
CFHR4 concentration in healthy single donor sera 
ranged from 6.5 µg/ml to 53.9 µg/ml with a mean 
value of 25.4 µg/ml. Similarly, the mean 
concentration of CFHR4 in the four tested pooled 
sera was 24.9 µg/ml (range 19.3-34.0 µg/ml). 
 
C3b binds to the C-terminal SCRs 8-9 of CFHR4A 
To investigate the relevance of C3b binding to 
CFHR4, we first analyzed the binding of C3b to 
CFHR4A, and compared it with the C3b binding 
to CFHR4B, which was previously shown to bind 
C3b and C3d (9, 10). C3b bound dose-dependently 
to both CFHR4 isoforms and to FH immobilized 
in microtiter plates (Figure 2A). The binding of 
C3b to CFHR4A and FH was comparable, but a 
weaker C3b binding to CFHR4B was observed 
(Figure 2A). Both CFHR4 isoforms also bound 
inactivated C3b (iC3b) and C3d, but not C3c (data 
not shown). 
Next, we mapped the binding sites for C3b 
using recombinant deletion mutants of CFHR4A. 
C3b only showed significant binding to CFHR4A 
deletion constructs that contained the C-terminal 
SCRs 8 and 9 (Figure 2B). A similar binding 
profile was observed for C3d (Figure 2C). 
We also analyzed CFHR4 binding to 
surface-bound C3b as it would occur on naturally 
opsonized surfaces. Binding of CFHR4A to 
immobilized C3b was compared to that of FH 
using the respective antisera (the specificities of 
the antisera are shown in Figure S1A). In contrast 
to FH, a rather weak binding of CFHR4A to C3b 
and iC3b was observed (Figure S1B). 
Because the immobilization on plate may 
affect C3b conformation and accessibility of 
binding sites, we analyzed, whether CFHR4A can 
bind to C3b that is bound covalently via its 
activated thioester bond to a natural surface. We 
used the yeast Saccharomyces cerevisiae as a 
complement activating surface (14). After 
exposure to normal human serum (NHS), the yeast 
cells were opsonized with C3 fragments as 
demonstrated by the strongly increased C3 signal 
compared to the buffer control (Figure S1C). 
CFHR4A and FH bound weakly even to non-
opsonized yeast cells and this binding increased 
when the yeasts were opsonized (Figure S1D). 
 
CFHR4A exhibits no significant complement 
inhibitory activities 
The capacity to enhance the cofactor activity of 
FH has been reported for CFHR4B (9). Therefore, 
we analyzed the CFHR4A isoform in fluid-phase 
cofactor assays (Figure S2A). CFHR4A displayed 
no own cofactor activity for the FI-mediated C3b 
cleavage (Figure S2A, lane 4) when compared 
with the control reaction containing C3b and FI 
only (Figure S2A, lane 1). Because weak cofactor 
activity has been reported for CFHR4B at very 
high and non-physiological concentrations 
(400 µg/ml) and extended incubation times (9), 
and also for the related CFHR3 (9, 15), we 
analyzed the cofactor activity of CFHR4A under 
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such conditions. Even after incubation of 
CFHR4A together with C3b and FI for five hours 
at 37°C, or at a concentration of 650 µg/ml 
(corresponding to 10 µM recombinant CFHR4A), 
no C3b degradation products were detected (data 
not shown). In comparison, C3b was readily 
cleaved in the presence of 10 µg/ml FH (67 nM) or 
4 µg/ml CFHL1 (80 nM) as cofactors (Figure 
S2A, lanes 2 and 5). Although CFHR4A displays 
no own cofactor activity, it enhances the cofactor 
activity of FH. This is demonstrated by the weaker 
intensity of the C3b α’-chain and the stronger 
intensity of the α’-41 fragment when compared to 
the incubation with FH alone (Figure S2A, lane 3 
in comparison to lane 2). Interestingly, CFHR4A 
had no detectable influence on the cofactor activity 
of CFHL1 (Figure S2A, lanes 5 and 6). 
Next, we analyzed, whether CFHR4A has 
decay accelerating activity. In solid phase 
convertase stability assays, CFHR4A when 
applied up to a concentration of 20 µg/ml 
(308 nM) displayed no own decay accelerating 
activity and did not influence that of FH (Figures 
S2B and S2C). 
Taken together, these and previously 
published data (9) indicate that CFHR4A and 
CFHR4B have no significant complement 
inhibitory functions at the level of C3b and the AP 
C3 convertase. 
 
CFHR4 activates the alternative complement 
pathway 
We have previously shown that CFHR4 activates 
C2/C4-dependent pathways via its interaction with 
CRP (12). To assess the role of CFHR4 in AP 
activation, we added human serum, diluted in Mg-
EGTA buffer to allow AP activation only, to the 
immobilized CFHR4 isoforms. Incubation with 
5% NHS led to a strong deposition of C3b on both 
CFHR4A and CFHR4B, whereas there was little 
increase in the anti-C3 signal on FH (Figure 3, 
white bars). No C3b deposition was detected for 
the CFHR4A deletion mutant SCR1-3 (containing 
the N-terminal CRP binding site), whereas strong 
C3b deposition, comparable to that of the whole 
proteins CFHR4A and CFHR4B, was detected for 
SCR4-9 (Figure 3). These results suggested that (i) 
CFHR4 activates complement via the AP and (ii) 
this activation is associated with the C-terminal 
part of the protein, which contains the C3b binding 
site. 
Complement activation via the AP is 
dependent on the formation of the AP C3 
convertase C3bBb, which assembles via the 
binding and activation of FB on C3b and is 
stabilized by properdin. We could indeed detect 
FB and properdin in parallel with the strong C3b 
deposition on both CFHR4 isoforms and the 
SCR4-9 deletion mutant. In contrast, the SCR1-3 
deletion mutant lacking a C3b binding site showed 
no AP complement activation as demonstrated by 
the absence of C3b, FB and properdin (Figure 3). 
The convertase components were also not 
detectable on the control proteins FH and human 
serum albumin. Similarly, deposition of C3b on 
CFHR4A, CFHR4B and SCR4-9 was detected 
from C2-depleted human serum but not from FB-
depleted serum (data not shown). 
 
CFHR4-bound C3b initiates the formation of an 
active AP C3 convertase 
Given the association of AP activation with the C-
terminal part of CFHR4 that contains the C3b 
binding site, we asked, whether CFHR4-bound 
C3b may serve as a platform for the assembly of 
AP C3 convertases. To this end, CFHR4A and its 
deletion mutants SCR1-3 and SCR4-9 were 
immobilized on microtiter plates, preincubated 
with C3b, followed by the addition of factors D 
and B in the presence of properdin to allow the 
formation of a C3bBb convertase. Binding of FB 
to the CFHR4-bound C3b (FB does not bind itself 
to CFHR4, data not shown), indicating the 
assembly of the C3 convertase, was detected on 
CFHR4A and SCR4-9, but not on SCR1-3 (Figure 
4A). To analyze, whether this CFHR4-C3bBb 
convertase is active, it was incubated with 
10 µg/ml C3. Measurement of generated C3a 
indicated that this convertase indeed cleaves C3 
into C3a and C3b and thus activates the AP, 
similar to the control C3bBb convertase that was 
assembled in parallel directly on immobilized C3b 
(Figure 4B). 
We also analyzed, whether the CFHR4 
ligand CRP influences the interaction of CFHR4 
with C3b and thus interferes with the formation of 
the CFHR4-C3bBb C3 convertase. In competitive 
ELISA, the binding of C3b, which was added in a 
constant concentration to immobilized CFHR4A, 
was not inhibited by up to 10-fold concentrations 
of CRP and vice versa (data not shown). Likewise, 
CRP did not inhibit the assembly of the CFHR4A-
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C3bBb convertase (data not shown). Thus, CRP 
and C3b can bind simultaneously to CFHR4A, 
allowing complement activation via the classical 
and the alternative pathways in parallel. 
 
The CFHR4-C3bBb C3 convertase shows 
resistance against the FH-mediated decay  
We next analyzed the stability of the CFHR4A-
C3bBb convertase compared to the C3bBb 
convertase. To this end, both types of solid-phase 
convertases were assembled in microtiter plate 
wells, and their spontaneous decay over time as 
well as their decay in the presence of FH were 
measured. The spontaneous decay of both 
convertases was comparable (data not shown). 
However, the CFHR4A-C3bBb convertase 
showed resistance against the decay accelerated by 
FH compared to the C3bBb convertase (Figures 
5A and 5B). Whereas the decay of the C3bBb 
convertase was strongly accelerated even at very 
low FH concentrations, higher amounts of FH 
were necessary to dissociate a similar amount of 
the CFHR4A-C3bBb convertase (Figure 5A). This 
effect was even more apparent when the decay of 
both convertases in the presence of a low FH 
concentration (2 µg/ml) was measured over time 
(Figure 5B). These results were confirmed by the 
measurement of C3a in the supernatants after 
adding C3 to the convertases. Generation of C3a 
from C3 by the C3bBb convertase was strongly 
reduced even at low FH concentrations (Figure 
5C, white bars), whereas the inhibitory effect of 
FH on the activity of the CFHR4A-C3bBb 
convertase was significantly lower, i.e. requiring 
more FH to achieve the same effect (Figure 5C, 
black bars). At 20 µg/ml FH, C3a levels were 
reduced by approximately 40-50% for the 
CFHR4A-C3bBb convertase as compared to 
nearly 90% for the C3bBb convertase. In 
conclusion, the decay of the CFHR4A-C3bBb 
convertase is less efficiently accelerated by FH 
compared to that of the C3bBb convertase. 
 
Mutation of conserved residues of the C3b binding 
site in CFHR4 significantly reduces C3b binding 
and AP complement activation 
The molecular basis of C3b binding to SCRs 19-
20 of FH was analyzed recently (16, 17). All 
CFHR proteins contain domains that are 
homologous to these C-terminal FH domains as 
shown by alignment in Figure 6. Kajander et al. 
propose that the FH C-terminus contains two 
C3b/C3d binding sites. Key residues of the SCR19 
site, namely D1119 and Q1139, and also K1188, 
are conserved in the FH protein family, whereas 
T1184, R1203 and K1230 of the SCR20 site are 
found in FH and CFHR1 only (16) (Figure 6). We 
assumed that C3b binding by CFHR4 is likely 
mediated by the same conserved residues that 
make up the SCR19 C3b binding site in FH. To 
analyze this, we generated mutants of the 
CFHR4B isoform in which these key residues 
were substituted. CFHR4B D221G corresponds to 
the atypical hemolytic uremic syndrome-
associated mutation D1119G in FH. In CFHR4B 
D221G/K290A, the lysine that corresponds to 
residue K1188 in FH was substituted for an 
alanine, additionally. Both mutations were shown 
to reduce the C3b binding capacity of FH (16–19). 
The analysis of CFHR4B and its two 
mutant variants D221G and D221G/K290A by 
silver staining (calculated molecular weight of ~37 
kDa each) after expression and purification is 
shown in Figure 7A. In comparison to the wild-
type CFHR4B, C3b binding to the mutant proteins 
was reduced by approximately 50% for D221G 
and 90% for D221G/K290A (Figure 7B). The 
strongly reduced C3b binding also led to a 
significantly reduced AP complement activation in 
NHS diluted in AP-specific buffer by the 
D221G/K290A mutant (Figure 7C). The reduced 
C3b binding to the D221G mutant was still 
sufficient to activate the AP, leading to only a 
slightly reduced deposition of C3b, FB and 
properdin in this experiment (Figure 7C). 
 
DISCUSSION 
 
Members of the factor H protein family have 
evolved through several gene duplications. All 
CFHR genes retained exons that encode SCRs 
homologous to the FH C-terminus. For most 
CFHR proteins interaction with C3b mediated by 
the C-terminal domains has been demonstrated 
(6). However, the relevance of this is rather 
unclear, and the mechanisms by which CFHRs 
may influence complement activation and 
regulation via their interaction with C3b are not 
well established. 
C3b binding has been reported for 
CFHR1, CFHR3, CFHR4B and CFHR5 (9, 20–
22). CFHR1, CFHR3 and CFHR4B were shown to 
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bind to the C3d part of C3b via their C-terminal 
domains (9, 10, 22). Here we have extensively 
analyzed the interaction of the long CFHR4 
isoform CFHR4A with C3 fragments. Previous 
studies typically measured CFHR4B-C3b 
interactions using fluid-phase C3b (20). We found 
that both CFHR4 isoforms can bind soluble C3b, 
iC3b and C3d (Figure 2 and data not shown). 
Because CFHR4A contains additional domains 
compared to CFHR4B, in particular SCR4 that is 
related to SCR8 of CFHR4A and SCR4 of 
CFHR4B (88% amino acid sequence identity, 
Figure 1), which are implicated in C3b binding, 
we mapped the C3b/C3d binding domains of 
CFHR4A using several recombinant deletion 
mutants of this isoform (Figure 2). The stronger 
C3b binding to the SCR4-9 mutant compared to 
the SCR8-9 construct, and also to CFHR4A 
compared to CFHR4B (Figure 2B), as well as the 
lack of C3b binding to SCR2-4 suggest that SCR4 
may contribute to the interaction of CFHR4A with 
C3 fragments, but does not mediate C3b binding 
itself. 
Although sharing a relatively high 
sequence identity in general, the C-terminal 
domains of FH family proteins show differences, 
leading to functional diversification. Recently, the 
structural basis of C3b binding by FH via SCRs 
19-20 has been resolved, indicating the presence 
of two binding sites (16, 17). Residues of these 
C3b-binding sites are differently conserved within 
the homologous domains in the FH protein family. 
Whereas the key residues of the SCR19 site (FH 
D1119, Q1139 and K1188) are found in all five 
CFHR proteins, those of the SCR20 site (FH 
T1184, R1203 and K1230) are all shared by 
CFHR1 only (and partly by CFHR2) (Figure 6) 
(16). Here, we show by site-directed mutagenesis 
that two residues in CFHR4, namely D221 and 
K290 in CFHR4B (corresponding to D468 and 
K537 in CFHR4A) that are homologous to key 
residues of the FH ‘SCR19-site’, are indeed 
involved in C3b binding (Figure 7B). The lack of a 
FH SCR20-homologue C3b-binding site in 
CFHR4 might explain its weak binding to surface-
bound C3b. In FH, one of the key residues of the 
SCR19 C3b-binding site (K1188) lies in SCR20 
(16). This might explain, why the FH SCR19-
homologue SCR4 of CFHR4A showed no 
significant C3b/C3d binding in the SCR2-4 
deletion mutant, which lacks an adjacent SCR20-
homologue domain (Figures 1 and 2B). 
Surface plasmon resonance studies to 
investigate the two closely related proteins 
CFHR4B and CFHR3 applied C3b immobilized 
on the surface of sensor chips (9). In our assays, 
we found no significant binding of CFHR4A to 
C3b immobilized non-specifically on a plastic 
surface (Figure S1B). Weak binding of CFHR4A 
was detectable on S. cerevisiae with C3b naturally 
deposited on the surface (Figure S1D). However, 
because binding of CFHR4A to the surface of 
opsonized yeasts was relatively weak and even 
weaker than that of FH, we conclude, that CFHR4 
binding to surface-bound C3b is unlikely to be of 
major physiological significance. In line with this, 
the previously reported binding of recombinant 
CFHR4B to C3b-opsonized pneumococci was 
very weak (9). 
For CFHR4B and CFHR3 a very weak 
cofactor activity for the FI-mediated cleavage of 
C3b at high, rather non-physiological 
concentrations has been reported (9). Recently, 
such an activity has been reported for CFHR3 at 
markedly lower concentrations (15). In addition, 
weak cofactor activity was also reported for 
CFHR5 (23). This is somewhat unexpected as all 
CFHRs lack domains homologous to the N-
terminal complement inhibitory region of FH. All 
these studies missed to identify the mechanism(s) 
and the domains behind such activities. We have 
thoroughly analyzed the long isoform CFHR4A, 
which contains all the domains that make up the 
short isoform CFHR4B, in cofactor assays with 
concentrations and incubation times exceeding 
those of the initial study (9) and found no such 
activity (Figure S2A). 
CFHR4B and CFHR3 were both shown to 
enhance the cofactor activity of FH and it was 
speculated that this activity might be based on 
conformational changes of the C3b molecule upon 
CFHR binding (9). We also found enhancement of 
the FH cofactor activity by the long isoform 
CFHR4A. This effect was, however, not evident 
when using CFHL1 instead of FH as cofactor 
(Figure S2A). In addition, in our assays, CFHR4A 
displayed no decay accelerating activity nor it 
influenced FH in this function (Figure S2). 
Altogether, except for the weak FH 
cofactor enhancing activity also reported for 
CFHR4B, CFHR4A did not show any complement 
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inhibitory activity at the level of C3b under the 
studied conditions. Thus, CFHR4 lacks FH-like 
complement regulatory activities. The weak FH-
cofactor enhancing activity of CFHR4 is unlikely 
to be of major physiological relevance, since (i) 
the plasma concentration of CFHR4 (~25 µg/ml) 
is significantly lower than that required for a 
detectable activity, and (ii) much less amounts of 
the potent complement inhibitors FH and CFHL1 
than found in body fluids were sufficient for 
effective control of complement activation via C3b 
inactivation or decay acceleration. 
Moreover, we observed complement 
activation rather than inhibition when CFHR4 was 
incubated with serum. Previously we have 
demonstrated that CFHR4 activates C2/C4-
dependent pathways via its interaction with CRP 
(12). Here, we found that CFHR4 can initiate AP 
activation via the formation of active C3 
convertases on CFHR4-bound C3b (Figures 3 and 
4). Because complement is autoactivated in human 
plasma via the spontaneous hydrolysis of the 
thioester bond in C3 (‘tick-over’ mechanism) that 
generates trace amounts of C3b via the very short-
lived C3(H2O)Bb initial AP C3 convertase (24, 
25), the activation of the AP via CFHR4-bound 
C3b can occur independently from the activation 
of the classical pathway via CFHR4-bound CRP 
(12). 
Activation of the AP through C3b bound 
by complement activatory host molecules might 
represent a mechanism to enhance opsonization 
and phagocytosis. Recently, properdin was shown 
to provide a platform for such a de novo 
convertase via C3b binding and thereby to initiate 
complement activation on target surfaces (26, 27). 
We propose that CFHR4 can similarly activate the 
AP on surfaces where it is able to bind. CFHR4 
was shown to bind to necrotic cells (11) and also 
to certain pathogens, such as Fusobacterium 
necrophorum (28) and the yeast Candida albicans 
(29). In our experiments both CFHR4A and FH 
bound weakly to S. cerevisiae cells (Figure S1D). 
By activating complement, CFHR4 could 
contribute to the opsonization and enhanced 
opsonophagocytosis of microbes and damaged 
host cells, provided that its interaction sites for 
ligands that mediate complement activation are 
still accessible in its surface-bound state. This was 
shown for CRP which is recruited by CFHR4 to 
the surface of necrotic cells (11). 
The assembly of alternative forms of C3 
convertases, like the herein reported CFHR4A-
C3bBb C3 convertase, might be relevant in light 
of their stability and regulation by complement 
inhibitors, such as FH. As we have demonstrated, 
the CFHR4A-C3bBb C3 convertase displays 
certain resistance against the FH-mediated decay 
(Figure 5). This could ensure enhanced 
complement activation and C3b deposition on 
target surfaces on the one hand, and a limited 
proceeding of the complement cascade to the 
terminal steps due to the binding of FH, and 
possibly other regulators, on the other hand. Such 
a scenario could occur on surfaces where both 
CFHR4 and FH bind (e.g., late apoptotic and 
necrotic cells) (11, 30), and would allow sufficient 
complement activation and C3b deposition 
without inflammation until the particle is 
eliminated via phagocytosis. 
Previously we have shown that CFHR4 
binds pentameric CRP both at low concentrations 
(such as in the plasma of healthy individuals) and 
at acute-phase concentrations (e.g., in the plasma 
of sepsis patients) and thereby activates 
complement (12). Here, we found that C3b- and 
CRP-mediated complement activation by CFHR4 
could take place simultaneously, as the two 
ligands do not interfere with the binding of each 
other and CRP did not interfere with C3 
convertase formation and activity (data not 
shown). This is explained by the spatially 
separated C3b and CRP binding sites within 
CFHR4. Because C3 fragments generated via 
CRP-mediated complement activation can 
potentially bind back to CFHR4, it is possible that 
AP C3bBb convertases are formed secondary to 
CRP binding and amplify CFHR4-mediated 
complement activation. 
In conclusion, we identify a new function 
for CFHR4 in the activation of complement via the 
AP by allowing the assembly of an active C3 
convertase. Thus, CFHR4 appears as a molecule 
that is able to recruit CRP to specific surfaces (11) 
and also to bind fluid-phase C3b, and through 
these two mechanisms can activate complement 
via different pathways and enhance local 
opsonization. These capacities distinguish CFHR4 
as a complement activatory molecule that 
enhances target opsonization from the complement 
inhibitor FH. It will be interesting to see, whether 
some of the other CFHR proteins share this ability 
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of CFHR4 to activate AP via their interaction with 
C3b. 
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FOOTNOTES 
 
1 The abbreviations used are: AP, alternative pathway; CFHL1, complement factor H-like protein 1; 
CFHR, complement factor H-related protein; CRP, C-reactive protein; FB, factor B; FD, factor D; FH, 
factor H; FI, factor I; FP, properdin; HSA, human serum albumin; NHS, normal human serum; SCR, 
short consensus repeat  
 
 
FIGURE LEGENDS 
 
FIGURE 1. Domain composition of the CFHR4 isoforms and FH. The SCR domains of the two 
CFHR4 isoforms are aligned to the most related domains in FH based on amino acid sequence identity. 
The numbers above the CFHR4 domains show the amino acid sequence identity to the corresponding FH 
domain in percentage. Domains of CFHR4 are homologous to the FH domains SCRs 6, 8, 9, 19 and 20. 
SCRs 1 and 6-9 of CFHR4A are identical to the SCRs that represent the shorter CFHR4B isoform 
(indicated by shading). CFHR4A contains four additional SCRs (SCRs 2-5) that differ in amino acid 
sequence from the SCRs that are common in both isoforms. The CFHR4 isoforms lack domains that are 
homologous to the N-terminal complement regulatory region (SCRs 1-4) of FH, but contain SCRs that are 
homologous to the FH C-terminus. SCRs 19-20 of FH and SCRs 4-5 of CFHR4B have been shown to 
bind C3b and C3d. Both CFHR4 isoforms harbor a binding site for native pentameric CRP in their SCR1. 
 
FIGURE 2. C3b binding to CFHR4A is mediated by SCRs 8-9. Binding of C3b to the immobilized 
CFHR4 isoforms and CFHR4A deletion mutants was analyzed in ELISA. A. C3b was added in increasing 
concentrations to FH, CFHR4A and CFHR4B immobilized in equimolar amounts (50 nM). C3b binding 
was detected with a HRP-conjugated C3 antibody. Data shown are means + SD from duplicates of three 
independent experiments. B. Binding sites for C3b within CFHR4 were mapped with CFHR4A deletion 
mutants representing SCRs 1-3, 2-4, 5-7, 4-9 and 8-9. The full-length isoforms and the deletion constructs 
were immobilized at 250 nM concentration. Binding of 25 µg/ml C3b was detected as in A. Background 
binding to BSA was substracted. Data shown are mean values + SD of triplicates from three independent 
experiments. C. Binding of C3d (5 µg/ml) to the immobilized CFHR4 isoforms and CFHR4A deletion 
constructs was analyzed as described in B. Bound C3d was detected with a rabbit human C3d antiserum. 
Data show mean values + SD of triplicate measurements from three independent experiments. 
 
FIGURE 3. CFHR4 activates the alternative complement pathway. CFHR4A, its deletion mutants 
SCR1-3 and SCR4-9, CFHR4B, FH and human serum albumin (HSA) were immobilized in microtiter 
plates at 100 nM and incubated for 30 min at 37°C with 5% NHS in TBS containing Mg2+ and EGTA to 
allow alternative pathway complement activation only. Deposition of C3b and binding of factor B (FB) 
and properdin were measured by ELISA. Data shown are mean values + SD from three independent 
experiments performed in duplicates. 
 
FIGURE 4. An active alternative pathway C3 convertase assembles on CFHR4-bound C3b. The 
ability of CFHR4A to serve as a platform for the formation of an active C3 convertase from purified 
complement components was analyzed in solid-phase assays. A. CFHR4A and its deletion mutants 
SCR1-3 and SCR4-9 were immobilized at 100 nM in microtiter plate wells and incubated with C3b 
(30 min, 37°C). Unbound C3b was washed away and FB, factor D (FD), properdin (FP) and BSA were 
added for 1 h at 37°C to allow convertase formation. After washing, remaining FB as a measure of intact 
convertases was detected. Means + SD from duplicates of two independent experiments are shown. B. 
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The CFHR4A-C3bBb convertase was generated as described in A and was incubated with 10 µg/ml C3 or 
buffer for 1 h at 37°C. The supernatants were analyzed for generated C3a using a C3a ELISA kit. The 
C3bBb convertase formed on immobilized C3b was used as a control. Data shown are mean values + SD 
from two independent experiments performed in duplicates. 
 
FIGURE 5. The CFHR4A-C3bBb C3 convertase is less efficiently regulated by FH. The regulation of 
the convertase assembled on CFHR4-bound C3b by FH was analyzed in ELISA. A. Both the C3bBb and 
the CFHR4A-C3bBb convertases were assembled in microtiter plate wells as described in Figure 4. After 
exposure to increasing FH concentrations for 30 min at 37°C, intact convertases were detected with anti-
FB. Wells incubated with buffer only were set to 100%. Data shown are means + SD from two 
independent experiments performed in duplicates. B. The spontaneous decay and the decay of both types 
of convertases in the presence of 2 µg/ml FH were measured over time by detecting remaining FB. The 
remaining convertases after decay in the presence of FH are shown as percent of the spontaneous decay of 
the respective convertases. Mean values + SD of duplicates from two independent experiments are shown. 
C. C3a generation by the two different convertases after incubation with buffer or FH for 30 min at 37°C 
was compared by analyzing the supernatants as described in Figure 4B. Data are mean values + SD from 
duplicates of two independent experiments. 
 
FIGURE 6. Alignment of all SCRs of the FH family proteins that are homologous to SCRs 19-20 of 
FH. All CFHR proteins contain domains homologous to the C-terminal SCRs 19 and 20 of FH that harbor 
binding sites for C3b/C3d. Within SCRs 19-20 of FH two binding sites for C3b/C3d have been described 
(16). The FH SCR19 C3b-binding site is comprised of residues located within SCR19 and SCR20. The 
residues D1119, Q1139 and K1188 of this site were shown to be particularly important for the interaction 
with C3b. All three residues of this site are conserved within the related domains in the FH protein family. 
The most important amino acids of the second C3b-binding site formed exclusively by residues of SCR20 
are T1184, R1203 and K1230. In contrast to the SCR19 site, these residues are not conserved within the 
FH protein family and all three are present only in CFHR1. This suggests that a single C3b-binding site 
exists within CFHR4, which involves residues homologous to the FH SCR19 site. 
 
FIGURE 7. Analysis of CFHR4B C3b-binding site mutants. Mutations within the putative C3b binding 
site of CFHR4 were analyzed using mutated variants of the short isoform CFHR4B. A. Silver staining of 
recombinantly expressed CFHR4B, CFHR4B D221G and CFHR4B D221G/K290A. CFHR4B is 
composed of five SCRs and the recombinant protein has a molecular weight of approximately 37 kDa. B. 
Dose-dependent binding of C3b to immobilized CFHR4B and the CFHR4B mutants D221G and 
D221G/K290A. C3b binding was detected with a HRP-conjugated C3 antibody. Data shown are means + 
SD from three independent experiments performed in duplicates. C. The CFHR4B C3b-binding mutants 
were analyzed in complement activation assays. The immobilized proteins were incubated with 5% NHS 
in TBS containing Mg2+ and EGTA to allow AP complement activation only. Formation of the AP C3 
convertase was measured by the deposition of C3b, FB and properdin (FP) as in Figure 3. Data shown are 
means + SD from three independent experiments performed in duplicates. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
 
FIGURE S1. Binding of CFHR4 to surface-bound C3b is weak compared to that of FH. Binding of 
CFHR4A to surface-bound C3b was analyzed in ELISA. A. Analysis of the antibodies that were used to 
detect CFHR4A and FH. Binding of the antibodies to CFHR4A, FH and human serum albumin (HSA) 
immobilized at 100 nM is shown. Data represent mean values + SD of duplicates from two independent 
experiments. B. Binding of 50 nM CFHR4A and FH to C3b, iC3b and C3c immobilized on microtiter 
plates at a concentration of 50 nM was detected with the respective antibodies. Data are 
mean values + SD from two independent experiments performed in triplicates. C, D. S. cerevisiae yeast 
cells were immobilized on microtiter plate wells at a saturating concentration followed by blocking of 
non-specific binding sites and incubation with 7.5% NHS for 30 min at 37°C. Opsonization with C3 
fragments was confirmed using an anti-C3 antibody (C) and binding of 100 nM CFHR4A and FH to 
serum-opsonized and untreated yeast cells was measured using the respective antisera (D). Data are 
means + SD from two independent experiments performed in duplicates. 
 
FIGURE S2. Analysis of complement regulatory functions of CFHR4A. The role of CFHR4A in 
complement regulatory functions such as cofactor and convertase decay accelerating activities was 
analyzed. A. In a fluid-phase cofactor assay, C3b was incubated with FI alone (lane 1) or in the presence 
of FH (lane 2), CFHL1 (lane 5), CFHR4A (lane 4) and in the presence of CFHR4A in combination with 
FH or CFHL1 (lanes 3 and 6) for 45 min at 37°C. The samples were analyzed by SDS-PAGE and 
Western blotting using a HRP-conjugated anti-C3 antibody. FI-mediated cleavage of the C3b α’-chain 
resulted in characteristic fragments with mobilities of 68, 43 (iC3b1) and 41 (iC3b2) kDa and in the 
diminishing of the intensity of the α’-band. The proteins were used in molar ratios of 3:1:1:1:20 
(C3b:FI:FH:CFHL1:CFHR4A) corresponding to 35, 6, 10, 4 and 90 µg/ml, respectively. A representative 
experiment out of four independent repeats is shown. B. The AP C3 convertase C3bBb was assembled on 
C3b immobilized in microtiter plate wells by the addition of FB, FD, properdin and BSA for 1 h at 37°C. 
Remaining FB as a measure of intact convertases was detected after separate incubations with increasing 
concentrations of FH, CFHR4A and HSA for 30 min at 37°C. Data shown are mean values + SD of two 
independent experiments. C. C3bBb convertases assembled in microtiter plates as described in B were 
incubated with constant concentrations (2.5 µg/ml) of FH and increasing concentrations of CFHR4A (up 
to 20 µg/ml, corresponding to a molar ratio FH:CFHR4A of 1:20) or buffer only for 30 min at 37°C. 
Intact convertases were detected with anti-FB. A representative of two independent experiments is shown. 
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